Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Bevacizumab/Erlotinib Adds Another Option to Frontline EGFR+ NSCLC

April 10th 2019

Findings from the phase III NEJ026 study, presented at the 2018 ASCO Annual Meeting and now published in Lancet Oncology, showed that adding bevacizumab to erlotinib significantly improved progression-free survival versus erlotinib alone in patients with EGFR-positive, advanced nonsquamous non–small cell lung cancer.

Dr. Cerfolio on the Importance of Specialized Care in Lung Cancer

April 10th 2019

Robert J. Cerfolio, MD, director of the Lung Cancer Center, chief of clinical thoracic surgery, NYU Langone’s Perlmutter Cancer Center, discusses the importance of specialized care in lung cancer and sheds light on the current outlook of the disease.

Sequist Sheds Light on Osimertinib/Savolitinib Combo in MET-Amplified NSCLC

April 10th 2019

Lecia V. Sequist, MD, highlights the expansion cohort data from the TATTON study and explains how these findings could impact the treatment landscape of EGFR-mutant NSCLC.

Dr. Kim on Overcoming Resistance to TKIs in NSCLC

April 8th 2019

Chul Kim, MD, MPH, an attending physician at MedStar Health and an assistant professor of medicine at Georgetown University, discusses overcoming mechanisms of resistance to TKIs in non–small cell lung cancer (NSCLC).

Dr. Kohman Discusses Importance of Lung Cancer Screening

April 5th 2019

Leslie J. Kohman, MD, FACS, Distinguished Service Professor of Surgery, Upstate University Hospital, Upstate Cancer Center, discusses the importance of lung cancer screening.

Dr. Wallen on Surgery in Patients With Advanced Lung Cancer

April 4th 2019

Jason M. Wallen, MD, MBA, FACS, FCCP, associate professor of surgery, division chief of thoracic surgery, director of gastric and esophageal cancer program, medical director of the thoracic oncology program, Upstate University Hospital, discusses the role of surgery in patients with advanced-stage lung cancer.

Dr. Weckbaugh on the LIBRETTO-001 Trial in NSCLC

April 4th 2019

Brandon Weckbaugh, MD, an oncology fellow at the University of Missouri-Kansas City, discusses the results of the LIBRETTO-001 trial in the patients with non–small cell small cancer (NSCLC).

Dacomitinib Approved in Europe for Frontline EGFR+ NSCLC

April 3rd 2019

The European Commission has approved dacomitinib for the frontline treatment of adult patients with locally advanced or metastatic non–small cell lung cancer with EGFR-activating mutations.

Dr. Sequist on Rationale for TATTON Trial in EGFR-Mutant Lung Cancer

April 2nd 2019

Lecia V. Sequist, MD, MPH, thoracic medical oncologist and director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital Cancer Center, discusses the rationale for the TATTON trial in non–small cell lung cancer (NSCLC).

Dr. Goldberg Discusses the Diagnosis of Mesothelioma

April 2nd 2019

Sarah B. Goldberg, MD, MPH, assistant professor of medicine, Yale School of Medicine and Yale Cancer Center, discusses the diagnosis of patients with mesothelioma.

Data Support TMB as Marker for Durvalumab Activity in NSCLC

April 2nd 2019

Tumor mutational burden identified patients who obtained a survival benefit with the PD-L1 inhibitor durvalumab, as initial therapy versus chemotherapy for advanced non–small cell lung cancer, even though the primary analysis of the randomized trial showed no difference between treatment groups, according to a new analysis.

Pembrolizumab Shows Promising Antitumor Activity in Pretreated Patients With SCLC

April 2nd 2019

Pembrolizumab (Keytruda) demonstrated promising antitumor activity with durable responses in patients with pretreated advanced small cell lung cancer.

Osimertinib/Savolitinib Pairing Is Active in Relapsed EGFR-Mutant, MET-Amplified NSCLC

April 1st 2019

The combination of osimertinib and the MET inhibitor savolitinib demonstrated encouraging clinical activity and an acceptable risk-benefit profile in patients with EGFR-mutant, MET-amplified non–small cell lung cancer who previously received EGFR TKIs.

Dr. Li on the Application of Liquid Biopsies in Lung Cancer

March 30th 2019

Bob T. Li, MD, MPH, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the application of liquid biopsies in lung cancer.

Tumor Mutational Burden Poses Challenges as Immunotherapy Biomarker

March 29th 2019

Although TMB is associated with responses to checkpoint inhibitor therapy, more research is needed to better understand how TMB interacts with other genomic correlates of the immune cycle before the biomarker can be incorporated into clinical practice.

Dr. Vallieres on Comparing VATS to Robotic Surgery in Lung Cancer

March 29th 2019

Eric Vallieres, MD, medical director, Division of Thoracic Surgery, Swedish Medical Center, discusses comparisons between video-assisted surgery and robotic surgery in the treatment of patients with lung cancer.

Dr. Padda on Next Steps for Treatment of EGFR+ NSCLC

March 29th 2019

Sukhmani Padda, MD, assistant professor of medicine, Stanford University Medical Center, member, Stanford Cancer Institute, discusses next steps for treatment of EGFR-positive non–small cell lung cancer.

Dr. Levy on Entrectinib in Oncogene-Driven NSCLC

March 29th 2019

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the use of entrectinib in patients with NTRK-mutant and ROS1-rearranged non–small cell lung cancer.

Prophylactic Cranial Irradiation Reduces Risk of CNS Metastasis, Improves DFS in Locally Advanced NSCLC

March 28th 2019

The use of prophylactic cranial irradiation failed to demonstrate a statistically significant improvement in overall survival over observation in patients with locally advanced stage III non–small cell lung cancer; however, the modality did improve disease-free survival and decreased the risk of brain metastasis.

Dr. Graziano on Sequencing Targeted Therapy in NSCLC

March 28th 2019

Stephen L. Graziano, MD, professor of medicine, division chief of medicine, and division chief of Upstate Cancer Center Adult Hematology/Oncology at the Upstate University Hospital, discusses sequencing targeted therapy for patients with non–small cell lung cancer (NSCLC).